ID: ALA3613598

Max Phase: Preclinical

Molecular Formula: C22H26N6O3

Molecular Weight: 422.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1cccc(NC(=O)C2(CN)CCN(c3ncnc4[nH]cc(C)c34)CC2)c1

Standard InChI:  InChI=1S/C22H26N6O3/c1-14-11-24-18-17(14)19(26-13-25-18)28-8-6-22(12-23,7-9-28)21(30)27-16-5-3-4-15(10-16)20(29)31-2/h3-5,10-11,13H,6-9,12,23H2,1-2H3,(H,27,30)(H,24,25,26)

Standard InChI Key:  KFGVCKLINBSYTQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 422.49

Molecular Weight (Monoisotopic): 422.2066

AlogP: 2.24

#Rotatable Bonds: 5

Polar Surface Area: 126.23

Molecular Species: BASE

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.39

CX Basic pKa: 9.16

CX LogP: 2.41

CX LogD: 0.64

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.54

Np Likeness Score: -0.93

References

1. Boland S, Bourin A, Alen J, Geraets J, Schroeders P, Castermans K, Kindt N, Boumans N, Panitti L, Vanormelingen J, Fransen S, Van de Velde S, Defert O..  (2015)  Design, synthesis and biological characterization of selective LIMK inhibitors.,  25  (18): [PMID:26233434] [10.1016/j.bmcl.2015.07.009]

2. Manetti F..  (2018)  Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.,  155  [PMID:29908439] [10.1016/j.ejmech.2018.06.016]

Source

Source(1):

• Scientific Literature